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Abstract
Background. Radiofrequency ablation (RFA) has been increasingly utilized for treatment of hepatocellular carcinoma (HCC).
Long-term results of RFA, especially in comparison to surgical resection, have not been well described.
Methods. Eighty-seven patients with single nodule HCC underwent surgical resection (N=47) or RFA (N=40) during a
9-year period. RFA was performed for 36 unresectable disease and 4 surgical refusals. Each group was further divided based
on tumor size for analysis; Group 1: resection,45 cm (N=18), Group 2: RFA,45 cm (N=26), Group 3: resection,45 cm
(N=29) and Group 4: RFA, 45 cm (N=14). Follow-up ranged from 2 to 72 months (median 16 months). Patients’
characteristics, local recurrences and overall and disease-free survivals were compared.
Results. Patients who underwent RFA were older (69 versus 60, p=0.0006), had more advanced Child-Pugh class and TNM
stage (p=0.0002 and p=0.016, respectively), and had smaller tumors (4.6 versus 7.4 cm, p=0.0032). Local recurrence rates
were 2% for resection and 10% for RFA (p=0.12). These local and other recurrences were subsequently treated with
multimodal therapies as indicated. The median overall and disease-free survivals were equivalent both between Groups 1 and
2 (49 versus 51 months, p=0.44, 36 versus 22 months, p=0.84), and Groups 3 and 4 (47 versus463 months, p=0.94, 28
versus 20 months, p=0.67).
Discussion. Although the groups were not truly comparable, this retrospective study suggests that RFA may offer similar long-
term results to surgical resection for single nodule HCC when combined with multimodal treatments.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most
common malignancies worldwide. Although it is rela-
tively uncommon in Western countries, its incidence is
rising [1]. Surgical resection and liver transplantation
are considered as the only potentially curative treat-
ments. The long-term results after surgical resection
have improved with recent reported overall 5-year
survival rates up to 50% [2]. Perioperative compli-
cations have also been reduced with improvements
in surgical and anesthetic techniques as well as peri-
operative patient management. The majority of HCC
occurs in cirrhotic liver and resection rates are only
10%–37% even in tertiary referral centers [3]. Liver
transplantation, the only alternative curative treatment
is also limited in its application due to donor shortage.
Local ablative treatments for HCC include per-
cutaneous ethanol injection, cryotherapy, laser, radio-
frequency ablation (RFA) and others. RFA has been
increasingly utilized because of its safety, versatility and
applicability. Because RFA is a relatively new treatment
modality, most reports in the literature are short-term.
There have been several studies with promising long-
term results [4,5]; however, how RFA compares with
surgical resection for HCC has not been well estab-
lished. In order to truly compare RFA and surgical
resection, randomized controlled studies are required.
This would be difficult to perform because many
believe surgical resection is the first-line treatment,
while RFA is reserved for unresectable disease. We,
therefore, retrospectively analyzed 87 patients with
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single nodule HCC who underwent either surgical
resection or RFA at two tertiary referral community
hospitals.
Methods
A total of 87 patients with single nodule HCC who
underwent surgical treatments between January 1995
and August 2003 at St. Francis Medical Center and
Kuakini Medical Center, Honolulu, HI, were retro-
spectively reviewed. Surgical decision making was
based on history, physical examination, laboratory
tests including complete blood counts, coagulation
profile, liver functions, ultrasound (US) or triple-phase
helical computed tomography (CT) findings. Hepatitis
B and C profiles and serum alpha-fetoprotein (AFP)
levels were obtained preoperatively. Surgical resection
was considered in Child’s A patients or early Child’s B
(Child-Pugh score of 7) patients without any evidence
of ascites or encephalopathy. HCC was diagnosed
pathologically by percutaneous biopsy or liver biopsy
done at the time of surgery. During the study period,
47 patients underwent surgical resection. Forty
patients underwent RFA, including 36 patients with
unresectable lesions or poor hepatic reserve and 4
patients who refused surgical resection. To facilitate
comparison among patients with equivalent tumor
size, each treatment arm was further divided into two
subgroups based on tumor size; Group 1: resection,
45 cm (N=18), Group 2: RFA, 45 cm (N=26),
Group 3: resection, 45 cm (N=29) and Group 4:
RFA,45 cm (N=14). Patients with multiple tumors
which were treated by resection or RFA and transplant
candidates were not included in this study.
RFA was performed under ultrasonographic
guidance, utilizing a generator providing 460 kHz
alternating current and a cannula with retractable
multi-pronged curved electrode-needles (RITA Medi-
cal System, Mountain View, California, or Radio-
therapeutics Corporation, Mountain View, California),
as previously reported [6,7]. Most procedures were
performed under general anesthesia in the operating
room by percutaneous, laparoscopic or laparotomy
approach. The average target temperature was set
at 100C to 110C, and ablation was continued for
5–30 minutes depending on the desired ablation size
(3–5 cm in diameter). The process was monitored
by real-time ultrasound to ensure 1-cm margins. For
large tumors, multiple overlapping ablations were
performed.
During follow up after RFA, a triple-phase helical
computed tomography was obtained one week post-
operatively, and then at 3-month intervals for one year
and at 4- to 6-month intervals thereafter. AFP was
measured a few weeks postoperatively, and then at 2-
to 4-month intervals. Similar follow-up was performed
after surgical resection. Whenever AFP re-elevated,
further imaging studies such as CT scan and gallium
scan were performed. Local recurrence was defined as
tumor recurrence at the treated site, whereas new
tumor which appeared in different hepatic parenchyma
was defined as new intrahepatic recurrence. For these
recurrences, RFA treatment or re-resection was con-
sidered and performed as indicated. Other patients
were considered for regional (transarterial chemo-
embolization or hepatic artery infusion chemotherapy)
or systemic chemotherapy. All patients were followed
for 2–72 months (median 16 months).
Patients’ characteristics including age, gender,
ethnicity, liver function, etiology of cirrhosis, AFP,
TNM stage (American Joint Committee on Cancer,
5th edition), Child-Pugh classification [8,9] were
compared among groups. Local and new intrahepatic
recurrence rates and overall and disease-free survivals
were assessed.
Data were collected retrospectively and analyzed
with SAS 8.02 for Windows (SAS Institute Inc.,
Cary, North Carolina) statistical software. Continuous
variables were expressed as mean+standard deviation
and significance between different groups was deter-
mined by chi-square test. Survival curves were evalu-
ated by Kaplan-Meier’s method and log-rank test was
used to assess significance between groups. For all
comparisons, significance was at 0.05 level.
Results
Patients who underwent resection were not completely
comparable to those who underwent RFA. These
demographics are summarized in Table I. There was
no difference in the male to female ratio, ethnicity,
AFP and risk factors of hepatitis C and alcohol.
Patients who underwent RFA were significantly older
and had more advanced TNM stage and worse under-
lying liver function as determined by Child-Pugh class.
Table I. Characteristics of patients by treatment
Resection
(N=47)
RFA
(N=40) p-value
Age (years) 60+12 69+10 0.0006
Male/female 29/18 19/21 NS
Tumor size (cm) 7.4+5.2 4.6+2.9 0.0032
AFP (ng/mL) 37,900+148,100 636+1724 NS
Etiology of cirrhosis
HBV 19 (40%) 7 (18%) 0.02
HCV 10 (21%) 16 (40%) NS
Alcoholic 8 (17%) 10 (25%) NS
Child-Pugh 0.0002
A 40 (85%) 18 (45%)
B 7 (15%) 18 (45%)
C 0 (0%) 4 (10%)
TNM Stage 0.016
1 5 (11%) 2 (5%)
2 37 (79%) 28 (70%)
3 3 (6%) 0 (0%)
4 2 (4%) 10 (25%)
AFP: alpha-fetoprotein; HBV: hepatitis B virus; HCV: hepatitis C
virus; NS: not significant.
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Table II. Characteristics of patients by treatment and tumor size
Group 1
Resection
45 cm
Group 2
RFA
45 cm p-value
Group 3
Resection
45 cm
Group 4
4RFA
5 cm p-value
Number of patients 18 26 29 14
Age (years) 61+9 67+10 0.048 60+13 72+10 0.005
Male/female 12/6 10/16 NS 17/12 9/5 NS
Tumor size (cm) 2.9+1.1 3.3+0.8 NS 10.2+4.7 7.1+3.7 0.034
AFP 648+1677 700+1814 NS 62735+188455 517+1603 NS
Etiology of cirrhosis
HBV 6 (33%) 4 (15%) NS 13 (45%) 3 (21%) NS
HCV 7 (39%) 15 (58%) NS 3 (10%) 1 (7%) NS
Alcoholic 5 (28%) 8 (31%) NS 3 (10%) 2 (14%) NS
Child-Pugh 0.024 0.014
A 14 (78%) 10 (38%) 26 (90%) 8 (57%)
B 4 (22%) 12 (46%) 3 (10%) 6 (43%)
C 0 (0%) 4 (15%) 0 (0%) 0 (0%)
Stage NS 0.0005
1 5 (28%) 2 (8%) 0 (0%) 0 (0%)
2 13 (72%) 23 (88%) 24 (83%) 5 (36%)
3 0 (0%) 0 (0%) 3 (10%) 0 (0%)
4 0 (0%) 1 (4%) 2 (7%) 9 (64%)
Table III. Local recurrence, new recurrence and overall survival based on treatment
Resection (N=47) RFA (N=40) p-value
Local recurrence 1 (2%) 4 (10%) NS
New recurrence 13 (28%) 10 (25%) NS
Overall survival NS
1-year 75% 78%
3-year 65% 58%
5-year 31% 39%
Median (months) 47 51
Figure 1. Overall survival of all patients according to treatment, resection versus RFA.
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Those who underwent resection had larger tumors and
were more likely to have hepatitis B. When patients
were divided into subgroups as shown in Table II,
some of these differences were no longer noted. In
patients with tumors of 5 cm or less (Groups 1 and 2),
those who underwent RFA were older and a higher
Child-Pugh score than those who underwent resection.
The mean tumor size was comparable between Groups
1 and 2. In patients with tumors larger than 5 cm
(Groups 3 and 4), those who underwent RFA were
older, had smaller tumors and had more advanced
Child-Pugh class and TNM stage.
Surgical resection was performed in 47 patients:
lobectomy (N=28), wedge resection (N=12), seg-
mentectomy (N=6), and trisegmentectomy (N=1).
There were four mortalities (9%) due to: myocardial
infarction (N=2), cerebrovascular accident (N=1)
and hemorrhage (N=1). Local recurrence developed
in one patient (2%) and new intrahepatic recurrence
developed in 13 patients (28%). Nine of these 14
recurrences were subsequently treated with multi-
modal therapies including transarterial chemo-
embolization (N=4), systemic chemotherapy (N=3),
re-resection (N=1), and RFA (N=1). At the time of
Table IV. Overall and disease-free survival based on treatment and tumor size
Group 1 Resection
45 cm
Group 2 RFA
45 cm p-value
Group 3 Resection
45 cm
Group 4 RFA
45 cm p-value
Number of patients 18 26 29 14
Overall survival NS NS
1-year 64% 83% 82% 65%
3-year 64% 53% 67% 65%
5-year 21% 32% 37% 65%
Median (months) 49 51 47 463
Disease-free survival NS NS
1-year 64% 71% 64% 53%
3-year 37% 31% 40% 44%
5-year 37% 23% 30% 0%
Median (months) 36 22 28 20
Figure 2. Overall survival of patients with tumors45 cm, Group 1 (resection) versus Group 2 (RFA).
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Figure 3. Disease-free survival of patients with tumors45 cm, Group 1(resection) versus Group 2 (RFA).
Figure 4. Overall survival of patients with tumors45 cm, Group 3 (resection) versus Group 4 (RFA).
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this analysis, 27 patients (57%) were alive. The most
common reason for death was liver failure, which
developed in seven patients (35%). Overall 1-, 3- and
5-year survival rates were 75%, 65%, and 31%
respectively (Table III).
RFA was performed in 40 patients by using a
percutaneous (N=24), laparoscopic (N=9) or open
surgical (N=9) approach. There was one mor-
tality (3%) secondary to liver failure. Complications
were noted in seven patients (18%), including
refractory ascites (N=3), pneumothorax (N=1),
pneumonia (N=1), cardiac arrhythmia (N=1) and
myoglobulinemia (N=1). Local recurrence devel-
oped in four patients (10%) and new intrahepatic
recurrence developed in ten patients (25%). Seven
of these 14 recurrences were subsequently treated
with multimodal treatments including transarterial
chemoembolization (N=5) and repeat RFA (N=2).
At the time of the analysis, 25 patients (63%) were
alive. All deaths were secondary to liver failure (15
out of 15, 100%). Overall 1-, 3- and 5-year sur-
vival rates were 78%, 58%, and 39% respectively
(Table III).
Overall survival curves between resection and RFA
were not different as shown in Figure 1 (p=0.79).
Overall and disease-free survival rates between those
with tumors of 5 cm or less (Groups 1 and 2) and those
with tumors larger than 5 cm (Groups 3 and 4) are
summarized in Table IV. Both overall and disease-free
survival curves were not different between Groups 1
and 2 as shown in Figures 2 and 3 (p=0.44 and 0.84,
respectively). Similarly, overall and disease-free sur-
vival curves were not different between Groups 3 and
4 as shown in Figures 4 and 5 (p=0.94 and 0.67,
respectively).
Discussion
HCC is the fifth most common cancer worldwide.
Although it is more prevalent in Asia and Africa,
the United States has witnessed a significant increase
in its incidence from 1.4 to 2.4 cases per 100,000
during the last two decades [1]. Although randomized
controlled studies are unavailable, surgical resection
and liver transplantation are considered by most as
the only potentially curative therapies [3]. Long-term
survival results after surgical resection have improved
recently and in institutions with extensive experience,
3- and 5-year survival rates are reportedly 68%–76%
and 51%–68% respectively [10]. However, only
selected patients are suitable for surgical resection
because of advanced tumors, major vascular invasion,
multifocal tumors, poor hepatic reserve or extrahepatic
disease. Resection rates are low (9%–37%) even in
high-volume centers [11]. Liver transplant is also
limited due to significant donor shortage.
Figure 5. Disease-free survival of patients with tumors45 cm, Group 3 (resection) versus Group 4 (RFA).
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In need of alternative treatments of unresectable
HCC, both systemic and locoregional therapies have
been investigated. Currently, among many local abla-
tive therapies including percutaneous ethanol injection
(PEI), acetic acid injection, cryotherapy, microwave
coagulation, laser and radiofrequency ablation, the last
has been most enthusiastically utilized. Rossi et al. [12]
first described RFA of human liver tumors in a large
study in the early 1990s, while the earliest recorded
use of heat to treat tumors dates back to Egyptian and
early Greek medical descriptions [13]. RFA uses the
energy of 450–500 kHz radiowaves to deliver hyper-
thermic ablation to target tissue. There are a number of
reasons that RFA is gaining the most popularity among
all the other local ablative therapies. First, RFA has
been proven to be safe by many authors with accept-
able complication rates [6]. With newer and larger
multiple probes, larger tumors can be ablated more
predictably. Also, RFA can be performed not only
percutaneously but also by laparoscopic or laparotomy
approach. This versatility encouraged some to con-
sider RFA as a first-line local palliative therapy for
unresectable HCC [11].
Because RFA is a relatively new treatment, the
majority of the literature describes safety, local control
efficacy, complication rates and early survival. There
are only few studies which reported long-term survival
data (Table V) [4,5,14–17]. Our survival rates after
RFA are comparable to previously reported long-
term results, although this study included only single
nodule HCC but did not exclude large (45 cm)
tumors whereas most others studied small tumors
(55 cm) including both single and multiple lesions.
Most recently Vivarelli [17] reported that the overall
survivals were significantly lower in RFA group than
resection group; however, the RFA-treated group had
significantly more patients with multiple lesions as
compared to resected patients, and there was no
statistical difference between the two treatments in
overall survivals when patients with single nodule were
compared.
Although these RFA results and historic controls
after resection are not comparable, recent data indicate
that RFA may offer equivalent survival results to
surgical resection [4,5,14–16]. In the present study,
local control efficacy and long-term survival rates were
not statistically different between those who under-
went resection with curative intent and those who
underwent RFA mostly for unresectable tumors. The
overall 5-year survival of the resection group was 31%
despite that neither large tumors (45 cm) nor Child B
was considered as contraindications for curative
resection.
This study included only patients with single nodule
HCC because tumor characteristics of patients with
multiple lesions who underwent resection or RFA
during the study period were rather heterogeneous.
We wanted to eliminate some of the discrepancies in
tumor characteristics such as bilateral versus unilateral,
vascular invasion and single nodule versus multiple.
Even within the group of patients with single nodule
HCC, many of patients’ characteristics were different.
Patients undergoing RFA had a few less favorable
characteristics such as age, TNM stage and Child-
Pugh class likely due to the unresectable nature of
HCC treated by RFA, but did have tumors that were
significantly smaller. When divided into subgroups,
however, the mean tumor size between Groups 1 and
2 was not different. Group 1 who underwent surgical
resection for tumors of 5 cm or less, and Group 2 who
underwent RFA for tumors of 5 cm or less, were more
comparable. This study showed similar survival rates
provided by resection versus RFA for patients with
tumors of 5 cm or less (Groups 1 and 2) as well as
those with tumors larger than 5 cm (Groups 3 and 4).
However, the study is limited as it is retrospective
and does not take into account what has been
accomplished by subsequent multimodal treatments.
In addition, this study evaluated a small number of
patients. Because HCC is an uncommon malignancy,
it is difficult to study large numbers of patients without
multicenter collaboration.
Neither of these modalities, even when combined
with other treatments, compares to the long-term
survival following liver transplantation. Liver trans-
plant for HCC is best performed in T1 and T2
lesions with a 5-year survival of 50%–60% [18]. More
recently, Tamura [19] and Jonas [20] reported 5-year
survival of 78% and 71% respectively. Ultimately,
the best management of HCC would involve preven-
tion of viral hepatitis, early detection and liver trans-
plant. Donor shortages prevent optimal management,
but perhaps living donor transplant may alter this
problem. Without sufficient organ donors, we are left
with resection or local ablation. While this study does
not define an algorithm how to use these modalities,
it does point out the potential differences in patients
who are candidates for each therapy. RFA allows us to
treat older patients and patients with more advanced
liver dysfunction, while resection allows us to treat
significantly larger tumors. With the multimodality
approach, similar long-term outcomes may be reached
both with RFA and resection.
Table V. Clinical studies on RFA for HCC with long-term overall
survival (53 years)
Author, Year
Number of
patients 1-year 3-year 5-year
Rossi, 1996 [4] 39 94% 68% 40%
Buscarini, 2001 [5] 88 89% 62% 33%
Iannitti, 2002 [14] 30 92% 60% NA
Guglielmi, 2003 [15] 53 87% 45% NA
Giovannini, 2003 [16] 56 96% 96% NA
Vivarelli, 2004 [17] 79 78% 33% NA
This study 40 78% 58% 39%
NA: not available.
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Is RFA equally effective as surgical resection for
localized tumors of 5 cm or less? Is RFA indicated
even for resectable HCC with curative intent? These
are highly controversial issues and prospective ran-
domized studies will be required to answer these
questions. Curley [21] stated that although RFA does
not replace standard hepatic resection, it may be
combined with partial hepatectomy for patients who
otherwise are not surgical candidates. Choti [22],
Guglielmi [15] and Lau [23] suggested the necessity
of controlled studies comparing RFA to resection.
However, prospective randomized studies would be
difficult to conduct, given surgeon and institutional
biases and patient preferences. The present study was
intended to attempt to evaluate RFA versus resection
in a retrospective fashion, in the hope that multiple
institutions will collaborate on retrospective data simi-
larly in the future. Should large retrospective studies
indicate similar outcomes between resection and RFA,
perhaps surgeon/institution biases can be put aside for
properly conducted randomized, prospective studies.
Conclusions
Although the groups were not completely comparable,
this retrospective study suggests that RFA may offer
similar long-term results to surgical resection for
single nodule HCC when combined with multimodal
treatments. Resection may be better used for a large
HCC, while RFA can be performed for an unresectable
HCC with advanced liver dysfunction.
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